CJC-1295
Also known as: CJC-1295 with DAC
CJC-1295 is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29) originally developed by ConjuChem. The name historically refers to the DAC-modified (Drug Affinity Complex) form that covalently binds serum albumin, producing a 6–8 day half-life; a separate no-DAC form (also called Modified GRF 1-29) shares the same tetrasubstituted backbone but lacks the albumin-linking maleimidopropionyl-lysine and has a half-life of roughly 30 minutes. Not FDA-approved in any form; ConjuChem halted Phase 2 development around 2007 after a patient death in an HIV-lipodystrophy trial (ultimately judged by investigators to be unrelated to the drug, but development was terminated regardless).
Pricing for CJC-1295
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for CJC-1295
75 third-party tests across 17 vendors. Each card links to the full report.
For
CJC-1295
by Peptide Supply Co.· batch CJC05192026
For
CJC-1295 without DAC
by OROS Research· batch OR-LP-CJCND5-526-B5
For
CJC-1295 DAC
by Verified Peptides· batch CJD06261105J
For
CJC-1295 DAC
by Verified Peptides· batch CJD06261105J
For
CJC-1295 No DAC
by Verified Peptides· batch cmp4wgbak004gx7rxaulax2wm
For
CJC-1295
by OROS Research· batch OR-LPCJC5-426-B5
For
CJC-1295
by Blank Peptides· batch 665394
For
CJC-1295 w/DAC
by Peptide Supply Co.· batch CD503232026
For
CJC-1295 with DAC
by Simple Peptide· batch CJCD05-032026-1
For
CJC-1295 (no DAC)
by Peptide Supply Co.· batch CJCND10031026
For
CJC-1295 DAC
by Glacier Aminos· batch CJCWDGA-01
For
CJC-1295 DAC
by Verified Peptides· batch CJD032610051
For
CJC-1295
by Glacier Aminos· batch CJCNDGA-01
For
CJC-1295 NO DAC
by Simple Peptide· batch CJND-01152026-H
For
CJC-1295 with DAC
by Simple Peptide· batch CJCD01122026-J
For
CJC-1295
by Ion Peptide· batch CND5-011226
For
CJC-1295 (NO DAC)
by MedGe Peptides· batch CND10N 07 26 2S
For
CJC-1295 (NO DAC)
by MedGe Peptides· batch CND10N 07 26 25
For
CJC-1295 (mod GRF 1-29)
by Crystal Peptides· batch cmojgrkug004j9grx3bnyc96w
For
CJC-1295 DAC
by Crystal Peptides· batch cmojgrkzh004k9grxx10m42l4
For
CJC-1295 DAC
by Verified Peptides· batch 01-26-0905H
For
CJC-1295 No DAC
by Verified Peptides· batch cmojb5hzx00w5kirxk8paai3q
For
CJC-1295 w/DAC
by Simple Peptide· batch CJCD11202025-J
For
CJC-1295 DAC
by Skye Peptides· batch CJCDA25-10-003
14 citations indexed for CJC-1295
review · 2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
Study · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
review · 2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Background Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.
Study · 2026
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration.
review · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.